Abstract

BH3-mimetics represent promising anti-cancer agents in tumors that rely on the anti-apoptotic function of B-Cell Lymphoma 2 (BCL2) proteins, particularly in leukemia and lymphoma cells primed for apoptosis. Mechanistically, BH3-mimetics may displace pro-apoptotic binding partners thus inducing BAX/BAK-mediated mitochondrial permeabilization followed by cytochrome c release, activation of the caspase cascade and apoptosis. Here, we describe a novel mode of caspase-independent cell death (CICD) induced by BH3-mimetics in a subset of diffuse large B-cell lymphoma (DLBCL) cells. Of note, rather than occurring via necroptosis, CICD induced immediately after mitochondrial permeabilization was associated with transcriptional reprogramming mediated by activation of c-Jun N-terminal Kinase (JNK) signaling and Activator Protein 1 (AP1). Thereby, CICD resulted in the JNK/AP1-mediated upregulation of inflammatory chemokines and increased migration of cytotoxic Natural Killer (NK) cells. Taken together, our study describes a novel mode of CICD triggered by BH3-mimetics that may alter the immune response towards dying cells.

Details

Title
Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines
Author
Yildirim, Nahide 1 ; Sarojam, Lakshmi 1 ; Smith, Victoria M. 2 ; Pieper, Nadja M. 1   VIAFID ORCID Logo  ; Anders, Marius 1 ; Jackson, Ross A. 2 ; Fuhrmann, Dominik C. 3   VIAFID ORCID Logo  ; Särchen, Vinzenz 1   VIAFID ORCID Logo  ; Brücher, Daniela 1 ; Weigert, Andreas 4   VIAFID ORCID Logo  ; Dyer, Martin J. S. 2 ; Vogler, Meike 5   VIAFID ORCID Logo 

 Goethe University Frankfurt, Institute for Experimental Pediatric Hematology and Oncology, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721) 
 University of Leicester, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, Leicester, UK (GRID:grid.9918.9) (ISNI:0000 0004 1936 8411) 
 Goethe University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721) 
 Goethe University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); a partnership between DKFZ and University Hospital Frankfurt, German Cancer Consortium (DKTK) partner site Frankfurt/Mainz, Frankfurt, Germany (GRID:grid.411088.4) (ISNI:0000 0004 0578 8220) 
 Goethe University Frankfurt, Institute for Experimental Pediatric Hematology and Oncology, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); a partnership between DKFZ and University Hospital Frankfurt, German Cancer Consortium (DKTK) partner site Frankfurt/Mainz, Frankfurt, Germany (GRID:grid.411088.4) (ISNI:0000 0004 0578 8220); Goethe-University Frankfurt, University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721) 
Pages
266
Publication year
2024
Publication date
Apr 2024
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3038446530
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.